GlaxoSmithKline: Pneumococcal Infections trials

The registry lists 32 Pneumococcal Infections studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 28 have results posted.

Phase 1 3Phase 2 3Phase 3 25Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedNCT05412030Phase 2Results posted
• A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccineCompletedNCT03803202Phase 1/2Results posted
• Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and OlderCompletedNCT02218697Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal InfectionCompletedNCT01746108Phase 3Results posted
• Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™CompletedNCT01641133Phase 3Results posted
• Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic TreatmentCompletedNCT01235949Phase 4Results posted
• Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850ACompletedNCT01175083Phase 3Results posted
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in NigeriaCompletedNCT01153893Phase 3Results posted
• Booster and Catch-up Vaccination With Vaccine GSK1024850ACompletedNCT01030822Phase 3Results posted
• Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese ChildrenCompletedNCT01027845Phase 3Results posted
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in MaliCompletedNCT00985465Phase 3Results posted
• Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed ChildrenCompletedNCT00950833Phase 3Results posted
• Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same VaccineCompletedNCT00911144Phase 3Results posted
• Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.CompletedNCT00829010Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of AgeCompletedNCT00814710Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of AgeCompletedNCT00808444Phase 3Results posted
• Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850ACompletedNCT00792909Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same VaccinesCompletedNCT00547248Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of AgeCompletedNCT00533507Phase 3Results posted
• Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up ScheduleCompletedNCT00513409Phase 2Results posted
• Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850ACompletedNCT00496015Phase 3Results posted
• Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of AgeCompletedNCT00489554Phase 3Results posted
• COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate VaccineCompletedNCT00466947Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedNCT00463437Phase 3Results posted
• Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm InfantsCompletedNCT00390910Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedNCT00345358Phase 3Results posted
• Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedNCT00344318Phase 3Results posted
• Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose ScheduleCompletedNCT00307034Phase 3Results posted
• A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorCompletedNCT04525599Phase 1
• Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy AdultsCompletedNCT01767402Phase 1
• Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in KoreaCompletedNCT01248988
• Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant VaccinesCompletedNCT00370318Phase 3